Agios Pharmaceuticals, Inc. (AGIO) Earnings Call Transcript & Summary

April 30, 2020

NASDAQ US Health Care Biotechnology earnings 74 min

Earnings Call Speaker Segments

Holly Manning

executive
#1

Thanks, Operator. Hi everyone, and thanks for joining us for Agios's First Quarter 2020 Conference Call. You can find slides for today's call in the Investors section of our website, agios.com. With me today to give prepared remarks are Dr. Jackie Fouse, our Chief Executive Officer; Dr. Chris Bowden, our Chief Medical Officer; Darrin Miles, our Senior Vice President of U.S. Commercial and Global Marketing; and Andrew Hirsch, our Chief Financial Officer and Head of Corporate Development. Dr. Bruce Car, our Chief Scientific Officer, will be with us for Q&A. Before we get started, I'd like to remind everyone that some of the statements we make on this call will include forward-looking statements. A range of risks, unknowns, and other elements could cause real outcomes and figures to vary significantly from anything suggested or stated in forward-looking remarks, among them the items described under the Risk Factors heading in the Form 10-K we most recently submitted to the SEC, along with any subsequent documents we file with that agency. On that note, I'll hand things over to Jackie.

Jacqualyn Fouse

executive
#2

Thank you, Holly. Good morning to all of you, and I appreciate you being on the call for our first quarter 2020 results. When this year began, we set out ambitious goals for 2020. Like everyone else across the globe, we had no way of knowing what difficulties would emerge from the COVID-19 pandemic's effects. The past several weeks have been difficult for all of us, in our personal lives and at work, while we adapt to the physical distancing rules that are now required and come to grasp, more deeply than before, how our actions can impact the people near us; we send our hopes for continued good health, physically and emotionally, to each of you, to our patients, to the healthcare systems and professionals, to our Agios team members and to humanity overall. No modern handbook exists for navigating a crisis of this kind, yet at Agios we quickly recalled what is most important: the well-being of our employees and their families, our communities and the patients we serve. First, in February, we activated both our organizational resiliency team and our clinical operations response team. Their job was to assess the emerging coronavirus outbreak and put together plans for dealing with how it would touch all parts of our business. Then, on March 10, we made the call that the majority of our staff—lab and field people included—would do their work from home, which we did to reduce the risk that the virus would be spread or that anyone would be exposed to it. That approach remains our policy today. Thanks to how we've built our supply chain, we've kept both our commercial and clinical medicines flowing without interruption. MyAgios, our patient assistance program, has continued to serve as a dependable source of support, helping people who are new to TIBSOVO as well as those already taking it remain on treatment—even patients whose coverage ended when they became unemployed. Our employees have been deeply committed, and together we've been out in our communities and standing behind healthcare workers: we organized giving Agios' stock of personal protective equipment to hospitals nearby, brought in over $22,000 for the Greater Boston Food Bank, and urged people to give blood. What I've seen from everyone over the past few weeks in terms of working together and pushing through has been genuinely impressive. It makes me optimistic that when we get past this difficult period, we'll emerge in a better position than we started. As for how our business has been affected, we revisited where we stand on priorities and settled on some significant choices about where resources go, so that we can keep executing on the things that matter most. While things remain disrupted and uncertain, our attention is on meeting our comp < > targets. That means pushing TIBSOVO's results, getting our late stage AML and glioma trials launched, and moving Mitapivat forward in several disease areas, and doing all of that while holding onto cash and building up our financial flexibility. Thanks to the choices we made about where to focus our resources, the amount of time our cash will last is now projected to stretch an additional half a year, taking us to June 2022. Later on this call, Andrew will go into more detail about the moves we've made. During my earlier remarks, I noted that back in February we put together a task force focused on clinical trials, with the goals of protecting the well-being of people enrolled in our studies and putting measures in place so that the greatest possible number of them could remain in those studies. We've handled this on an individual basis, consistent with what the FDA has advised. Chris will walk everyone through the impact on every program and trial, plus what our team has done to respond to the difficulties the pandemic has created. On the commercial side, TIBSOVO got off to a strong start this year, and revenues picked up speed during March and into April, which strengthens our confidence in the 2020 product revenue guidance we've given. Darrin will go into more detail about the trends we observed in Q1. Thanks to these efforts, we are still on track to reach our Agios 2025 strategic vision. Before I finish, I want to express my gratitude to every Agios employee for the amazing work you've done these past few weeks. Your resolve when facing adversity has truly saved lives, and I couldn't be prouder to be part of this team. Chris, I'll hand things over to you.

Chris Bowden

executive
#3

Thanks, Jackie. As I walk everyone through the clinical update, I'll describe where our study stands, using our current best guess about how the coronavirus pandemic is affecting things today. We serve as a partner and collaborator on over a dozen clinical trials, and our attention has been fixed on backing our sites, investigators, and the patients taking part in our studies while they cope with the pressure of COVID-19. As Jackie said, a clinical operations response team of ours gathers each day to size up the shifting situation and lessen disruption as much as we can, working patient by patient. I'll begin with Mitapivat, the lead PKR activator of ours, which right now is being studied in pyruvate kinase deficiency, thalassemia and sickle cell disease. During this year's first quarter, we hit a number of significant milestones for our most advanced program in PK deficiency. We could potentially deliver the first disease modifying therapy for this disease. In March, Mitapivat received a positive opinion on its application for orphan drug designation from the CHMP for treating adults with PK deficiency. Orphan drug designation from the EMA brings us a number of advantages, among them 10 years of market exclusivity. We also completed enrollment for the Phase 3 ACTIVATE study of Mitapivat, which involves PK deficiency patients who don't receive routine transfusions. In total, 80 patients were enrolled in the ACTIVATE-T trial for PK deficiency. Among those receiving regular transfusions, 27 patients were enrolled. For both trials, our priority right now is to make every effort to guarantee that participants can obtain the study drug and that clinical data gets collected, no matter whether a patient can physically reach their medical center. That involves home visits, telemedicine options, using local labs, and having drug delivered by courier. Based on what we know, thanks to these measures, not a single patient in these studies has gone without study drug so far. Since the main portion of both trials won't wrap up until later this year, we do expect hurdles when it comes to getting into sites for data < >, especially in regions hit hardest by the pandemic. Because of that, we now expect topline results from the two studies at some point from the close of 2020 through the midpoint of 2021. Under the assumptions we're working with today, approval for Mitapivat in PK deficiency is now looked for in 2022. Once we understand more clearly when sites taking part will permit monitoring visits, and how that access shapes our capacity to reach database lock after the final patient visit has taken place, we hope to tighten these timelines further. Turning to the Phase 2 trial of mitapivat in thalassemia: enrollment wrapped up earlier this year, with 20 patients, exceeding the 17 we had originally targeted. As you may recall, in December we presented proof-of-concept in thalassemia based on interim data from this study, showing that treatment with mitapivat yielded a hemoglobin response of at least 1 g/dL in 7 of 8 evaluable patients. Findings from 13 efficacy evaluable patients — a group that included individuals with both beta and alpha thalassemia — have been accepted for presentation at the European Hematology Association Congress in June, which is being held virtually this year. As we've said previously, Dr. Chan from the National Institutes of Health put forward data from the mitapivat sickle cell disease proof-of-concept trial for an EHA presentation. Those findings were accepted, but given the meeting's shift to a virtual format, the NIH decided against presenting them there and will instead submit them for the ASH Annual Meeting in December; our plan to reach a proof-of-concept decision on mitapivat in sickle cell disease < > 2020 is unchanged. The purpose of this trial is to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics for increasing oral doses of mitapivat. In addition to the 5 mg, 20 mg, and 50 mg b.i.d. doses studied under the initial protocol, Dr. Chan just changed the study so that those patients could get mitapivat at doses as high as 100 mg, taken twice a day, over a two-week period. As far as enrollment goes, Dr. Chan is looking to sign up as many as 25 patients for this study, though right now that process is on hold as a result of the COVID-19 pandemic. Beyond mitapivat, we've also come up with AG-946, which is a next generation PKR activator. Back in March, the FDA gave us clearance for the AG-946 IND application, and we're expecting to kick off a Phase 1 study in healthy volunteers around the middle of 2020. That Phase 1 study is going to evaluate AG-946 in roughly 32 healthy volunteers, using a single ascending dose cohort and then a multiple ascending dose cohort. We're looking at safety, tolerability, pharmacokinetics, and pharmacodynamics for AG-946 at a dose that could potentially treat patients. On top of that, if the safety and tolerability data back up continued dosing, there's an option built in to add more multi-ascending dose cohorts in adults who have sickle cell disease. Now I want to talk about our malignant hematology programs. There, our efforts center on expanding TIBSOVO, our IDH1 inhibitor, both geographically and across indications. First off, in the EU, regarding our TIBSOVO filing for relapsed and refractory AML, we got a day one 180 list of outstanding issues. Right now, we continue to expect a CHMP opinion toward the close of the year. When it comes to frontline AML, our main emphasis is on getting patients enrolled into worldwide Phase 3 combination trials, since that approach lets us bring an IDH1 indication to the greatest possible number of AML patients. The first of these is AGILE, a Phase 3 trial testing TIBSOVO together with azacitidine, while the second is the Cooperative Group HOVON150 trial, which pairs TIBSOVO and IDHIFA with standard induction and consolidation chemotherapy. Because this therapy is generally well tolerated within oncology, doctors keep sending patients our way for both trials, and patients have still been able to obtain TIBSOVO, even receiving shipments to their homes when needed. Even so, complications tied to the pandemic have come up: activating sites has slowed down, and enrollment has been halted at some locations. For the AGILE trial, our earlier forecast was that enrollment would wrap up by the close of this year, but Q1 holdups in activating sites in China plus enrollment interruptions worldwide mean completion is now anticipated during 2021. Lately, a number of Chinese sites have been permitted to reopen, and as nations emerge from the crisis and resume work settings like those before the pandemic, we anticipate offering a more exact timeline for finishing enrollment. For the HOVON150 study, most clinical trial locations sit in Europe, and enrollment has decelerated at sites in countries hit hardest. We remain fairly early in the accrual process, and given that this is a certainly long study, there may be room to recover some time as we go. Once every site is activated and accrual rates have been agreed upon, we will share an update regarding the expected completion of enrollment. Outside of AML, we have lately restarted the Myelodysplastic Syndrome portion of the Phase 1 study of TIBSOVO, aiming to generate the data needed to pursue a possible U.S. regulatory filing. Because we are at an early stage of reopening this study, delays have been encountered at sites beginning startup activities, and enrollment completion is now anticipated in 2021. To wrap up, I'd like to cover AG-636, the DHODH inhibitor we have in development. Right now, it's under evaluation in a Phase 1 trial that escalates dosing in patients with advanced lymphoma.

Chris Bowden

executive
#4

Earlier in the year, our plan was to reach a go or no-go call regarding continued work on AG-636 before 2020 ended. Consequently, because of the prioritization effort Jackie described, along with quite restricted enrollment in that trial—just 11 patients in total across a 10-month period—we've decided to halt development internally. Right now, our intention is to seek out a collaborator willing to put money into the program. Let me shift to solid tumors, where we're pushing forward pivotal trials of IDH inhibitors for cholangiocarcinoma and low grade glioma, plus assessing AG-270, a MAT2A inhibitor, combined with taxanes for pancreatic and lung cancers. During the prior year, we reported favorable results from the clarity Phase 3 trial of TIBSOVO in previously treated IDH-1 cholangiocarcinoma, which demonstrated that TIBSOVO lowered the chance of disease progression or death by 63%. Around the middle of 2020, we anticipate having mature overall survival results from that trial to back a possible supplemental NDA submission. Considering how the COVID-19 outbreak currently stands and what it has done to resources at trial sites, we foresee difficulties gathering the < > data from sites and carrying out the daily cleaning process. Because of that, the sNDA filing probably won't happen until somewhere between the end of 2020 and the middle of 2021. The INDIGO trial is our Phase 3 research on vorasidenib, our brain-penetrant IDH inhibitor, for low grade glioma, which began in December. At present we're seeing certain delays in startup and enrollment stemming from the pandemic. Because this trial is at an early stage and has a lengthy timeline, we'll probably recover some of that lost time as we go; we'll share an update on when we expect enrollment to finish once every site is activated and we have clearer insight into accrual rates; meanwhile, we're eager to present updated results from the Phase 1 trial of vorasidenib in non-enhancing low grade glioma at ASCO in late May. Finally, enrollment continues in the AG-270 Phase 1 dose escalation combination cohorts, though it has decelerated at certain sites since resources have been diverted due to the COVID-19 pandemic. We continue to expect that we can reach a go or no-go call on this program by no later than 2022. In closing, I want to express gratitude to our clinical operations response team, along with every one of our safety, medical, regulatory, and technical operations colleagues, for exceeding what duty requires over these past few months. The consequences of this crisis remain ongoing, and thanks to their dedication and guidance, we can stay up to date, assist our clinical trial partners, and reach choices that serve patients' best interests. With that, I'll hand things over to Darrin so he can cover our first quarter commercial results.

Darrin Miles

executive
#5

Thanks, Chris. I'm happy to report that we achieved a solid performance in the first quarter, with $23 million in net sales for TIBSOVO, which is 16% higher than the fourth quarter of 2019. This growth came mainly from more new prescriptions and refills across both the newly diagnosed and the relapsed and refractory AML groups. According to our market research, regimens that include TIBSOVO are viewed as standard of care for patients newly diagnosed with IDH1 mutation positive disease who cannot receive more intensive therapy, as well as for those in first relapse or refractory, and this is further shown by our measurement of patient share in both the newly diagnosed and first relapse settings. In terms of our promotional focus, we keep seeing that about half of TIBSOVO usage in both settings involves combination with a hypomethylating agent. Additionally, this growth is backed by ongoing expansion of the unique prescriber base, which rose 25% from Q4. Although we did observe the usual Q1 seasonal rise in patient assistance due to benefit changes implemented at the beginning of the year, the size of that increase was smaller than we anticipated, since underlying demand for TIBSOVO grew significantly during the quarter. Our patient assistance program, myAgios, remains fully operational throughout the COVID-19 pandemic as we assist patients during these difficult times. As Jackie noted, in light of rising concerns about the pandemic, our field team has been working from home since mid-March, and we've had success maintaining engagement with customers through tools that support remote interactions. The need to treat AML patients is urgent, and professional oncology guidelines prefer effective oral choices with well-tolerated safety profiles as healthcare professionals deal with the requirements of patients who have COVID-19. With these dynamics, TIBSOVO's efficacy, safety, and clinical benefit profiles make it a strong preferred option for treating IDH1 positive patients. These elements, along with sustained momentum in physician demand through April, give us confidence in our full year 2020 U.S. TIBSOVO net sales guidance of $105 million to $115 million. We'll keep watching market trends closely because of the continuing effects of the pandemic. I want to thank the outstanding team at Agios for meeting the challenges brought by COVID-19 and for continuing to deliver for our patients, our customers, and the business. I'll now hand it over to Andrew to go over our first quarter financials.

Andrew Hirsch

executive
#6

Appreciate that, Darrin. You can find our Q1 results in the press release that went out this morning, and I'll walk through the highlights. Additional specifics will be in the 10-Q we file later today. I'll begin with a look at the quarter, then go over a few of the cash preservation steps we've implemented that support our longer fund life < >.First quarter total revenue came in at $87 million, made up of $23 million in TIBSOVO net sales, $61 million in collaboration revenue, and $3 million in IDHIFA royalty revenue. The primary driver of the revenue growth versus last year was a $42 million rise in collaboration revenue.Because BMS told us they would not be extending the 2016 MIO research collaboration and would not choose a program to carry forward in < >, we recognized the bulk of the deferred revenue sitting on the balance sheet during the quarter.Looking ahead, the remainder gets recognized in Q2, running through the end of the research term in mid-May. Beyond that point, collaboration revenue will largely be made up of reimbursement for work we're doing on BMS' behalf tied to commercialization and development of IDHIFA, plus reimbursements under our < > agreement.Sequentially, revenue growth also got a lift from a $14 million increase in TIBSOVO net sales, which Darrin covered earlier. Gross to net was mostly in line with Q1 of 2019, and we finished the first quarter with channel inventory levels below where they stood in December, both in absolute units and in weeks of demand. Cost of sales for the quarter totaled $533,000.Now for operating expenses: R&D in Q1 was $91 million, down $4 million from the first quarter of 2019. That year-over-year decline in R&D was mainly due to milestone recognition for launching the HOVON150 Phase 3 study in Q1 of 2019, along with the wind-down of the TIBSOVO ClarIDHy Phase 3 study and the Phase 1 hematologic malignancy study.SG&A came to $39 million in the first quarter, which is $7 million higher than Q1 of 2019, driven by added head count supporting our U.S. operations and the initial gated infrastructure build in EU < >. We closed the quarter with $613 million in cash, cash equivalents and marketable securities.As Jackie mentioned at the top of the call, we've recently made key resource allocation decisions aimed at supporting execution of our critical business objectives while preserving cash and boosting our financial flexibility. As part of that effort, we took a hard look at spending across the business to capture the lower spend levels that will occur naturally from the global pandemic's impact, things like travel and clinical trial costs.On top of that, we chose to delay or cut spending on activities that are lower priority. The steps we're taking include halting work on AG-636, putting certain research initiatives on hold — among them the program focused on Friedreich's Ataxia — and pushing back the beginning of longer-term clinical trials that are needed but don't have time-sensitive deadlines for our primary clinical programs. We're also restricting new hires, apart from a limited set of positions that will assist us in developing essential capabilities, while substantially scaling back our contracted staff and postponing projects related to IT and facilities infrastructure. I want to stress that these choices were made because of the unpredictability that today's worldwide circumstances have brought into the financial markets, not because of any issue with liquidity. Consequently, we now anticipate that the cash balance at the close of Q1, together with projected product revenue and royalties — leaving out expected payments tied to specific program milestones — will be enough to support our existing operating plan through June 2022. With that said, operator, could you please open up the line for questions.

Tyler Van Buren

analyst
#7

Hi everyone, good morning, and it's wonderful to hear about the longer cash runway. I appreciate you answering our questions. So regarding Mitapivat in sickle cell, when you say the proof-of-concept decision is still expected around mid 2020 — and I realize the data is going to be presented at ASH — but when that decision comes at midyear, will any data be available to us, and if yes, what exactly will we get to see? And more specifically, to reach a proof-of-concept call or to proceed further, what do you need to observe?

Jacqualyn Fouse

executive
#8

Chris, would you like to handle that one?

Chris Bowden

executive
#9

Okay, good morning to everyone. This is Chris Bowden speaking, and here's what you ought to expect: topline results shared in a manner comparable to our thalassemia data presentation at ASH toward the close of last year, when we showed efficacy findings on that study's primary endpoint — the rise in hemoglobin — and offered a few high-level remarks regarding safety. Those among you who came to our investor event will recall that we additionally shared some data from individual patients. Because we'll be examining the data and assembling all of it, I'm unable to say exactly what today's announcement will contain. Regarding what's required for proof-of-concept — meaning advancement into the next phase of development — from an efficacy perspective, we're focused on two readouts. The first one tackles the hemolysis and anemia problems, while the second concerns findings we'd observe from the drug that might influence vaso-occlusive crisis. So essentially we're examining the oxygen dissociation curve, sickling curves < >, and ATP 2,3-DPG, occurring within red cells of patients receiving varying dose levels of treatment, and then naturally tracking them across their treatment course to see what shifts appear in hemoglobin, along with endpoints that would capture effects on erythropoiesis or the persistent, ongoing hemolysis. So I'd characterize it as a great deal of varied data that we'll be reviewing. And we look forward to being able to offer some — our interpretation of that data at midyear.

Tyler Van Buren

analyst
#10

And, quickly, as a follow-up, is there anything more you can share about why you decided to raise the dose to 100 milligrams, and given some of the difficulties you're having with enrollment in the near term, ought we to anticipate a meaningful number of patients receiving the 100 mg dose by year end?

Chris Bowden

executive
#11

Right now I'll take the second part of what you asked. With the steps that have been taken to deal with the pandemic, the hope is that they keep working, and the NIH hopes that once they believe they have a handle on all the matters they consider necessary for that, they will be able to start enrolling patients. As for the 100 milligram BID dose in pyruvate kinase deficiency, those patients were treated by us beginning at 300 mg b.i.d., the initial dose in our Phase 2 drive PK study; and in our ACTIVATE trials, now our pivotal studies, we move from 5 mg to 50 mg. In the thalassemia trial, two doses have been studied by us, 50 mg and 100 mg. So the NIH knew about this from the start, and during our first discussions with them, that range of doses, 5 to 50, those three doses 5, 20 and 50, was chosen by them to be studied so as to understand the PK and PD and effects on hemoglobin. And through our ongoing discussions with them and our sharing of data from thalassemia and certain other aspects, a decision has now been made by them to study 100 mg in the trial, and we're very grateful for that, since it will provide us a greater dose ranging experience when it comes to examining all those other endpoints I mentioned.

Tyler Van Buren

analyst
#12

Good, that’s really useful. Thank you for answering our questions.

Chris Bowden

executive
#13

Sure. Operator, do we have another question?

Darrin Miles

executive
#14

At this point, < > is set to go.

Anupam Rama

analyst
#15

Hi everyone, I really appreciate your taking my question. Looking at the finance angle and how we stretch the cash runway, what are you assuming regarding enrollment trends improving across the trials and the continued build-out of infrastructure? Also, should the pandemic drag on, which levers could be pulled or pushed that might allow the cash runway guidance to potentially be extended? Many thanks.

Jacqualyn Fouse

executive
#16

This is Jackie. Hello Anupam — Andrew will likely want to chime in here, but let me begin with a broad overview. As Andrew mentioned during his prepared remarks, certain expenses ought to decline due to the delays and simply remain lower, such as some T&E and similar items. A number of the remaining ones are likewise tied to gating depending on how the situation develops, meaning some of them might be gated for a prolonged stretch. Naturally, all of us are hoping that where clinical trial enrollment is concerned, activity resumes and returns to the enrollment curves we'd have projected prior to this, yet regardless, that at the very least shifts timelines out somewhat; so I'm not sure, Andrew, whether you'd like to add anything.

Andrew Hirsch

executive
#17

Yes, absolutely, yes. Anupam, I believe the steps I mentioned regarding what we're postponing or deferring apply across that period of runway. So, as you likely know well, the circumstances shift quite a bit, and we're ready to respond as things evolve. Consequently, I think additional options could emerge as business events play out over the course of this timeframe, though it's simply — predicting what those might be at this moment is just too difficult. Thus, we felt at ease that making these choices today was correct, to secure that runway lasting until June of 2022; and after that, we're watching the situation intently and will be in a position to react should it become necessary.

Anupam Rama

analyst
#18

Let me squeeze in one more quick question. Regarding ACTIVATE and ACTIVATE-T, Chris, I believe you mentioned that as of now, zero patients have skipped a dose. But what kinds of steps and approaches are you using to reduce the chance of losing follow-up data across the coming months? Thanks a lot.

Chris Bowden

executive
#19

Sure — our folks right now are concentrating on maintaining contact with the investigators, not only for the PKR program but across every one of our studies, as much as we can, together with our CRO partners, in terms of looking ahead to when patients reach key study visits, when a lab value might be required; and so what we're doing is adhering to guidance from the FDA and the EMA, in terms of doing whatever we can to collect all of that data. And then to record it, which I believe is going to be among the critical elements. As with any study, missing data always happens; so our aim is to truly pursue the important efficacy data, the important safety data, and to keep getting drug to patients the way we've managed to do. I believe there will definitely be a possibility that we'll have to assess how we would handle missing data, depending on how much there is and which data you mean, whether you approach it via different sensitivity analyses that might be talked over with the authorities, and so on. But right now, the general aim for us, and as far as we can determine, we've been fairly successful at keeping patients on treatment and obtaining the necessary data we need to gather. I think one of the largest effects you've heard from us in our prepared remarks concerns the pandemic, or elements involving accrual and then actually getting into sites to pull data out. So that's roughly, I think, what Andrew described as a dynamic situation — this keeps changing, some locations are improving and the smoke is beginning to clear somewhat, while in other locations we're still handling it one day at a time, one patient at a time, one site at a time.

Anupam Rama

analyst
#20

Great, appreciate you letting us ask.

Peter Lawson

analyst
#21

Hello, and thank you for fielding my questions. I just wanted a bit of guidance on revenues — if you could share any additional specifics regarding possible off-label use that you're observing, or a rise in off-label prescribing, and also whether prescriptions are being written for longer durations, plus any shifts in inventory, that would be helpful. Thanks.

Jacqualyn Fouse

executive
#22

Darrin, would you like to…?

Darrin Miles

executive
#23

Yeah, this is Darrin. Glad to discuss that. Our visibility is limited when it comes to utilization in expanded indications or extended disease settings. We know there's use beyond AML, such as in cholangio and glioma, but right now I'm unable to provide an exact figure. And then — I believe the other piece of what you asked had to do with inventory? Is that right?

Peter Lawson

analyst
#24

Yep. Correct. Yep.

Darrin Miles

executive
#25

Perhaps I could send it over to you, Andrew, or should I handle it?

Andrew Hirsch

executive
#26

Absolutely, I don't mind addressing that at all. Yeah, I'd say it basically comes down to how shipments are scheduled, you know. The quarter wrapped up on a Monday and a Tuesday, and usually in those situations, you're seeing goods go out, and we only book revenue once it's actually been received. So it's simply a matter of timing quirks and the way shipping schedules fall.

Peter Lawson

analyst
#27

Great, thank you. And then just on the…

Jacqualyn Fouse

executive
#28

I'm sorry. What I was about to say is there's perhaps one point worth noting, since I think it was kind of embedded in your question: honestly, the mix of the scripts hasn't shifted very much between Q4 and Q1 when it comes to the split between monotherapy, as well as combination with azacitidine or hypomethylating agents in AML. So I think that maybe is worth noting. We haven't seen any impact from the pandemic in terms of the general dynamics of how the drug is being used.

Andrew Hirsch

executive
#29

I might just add one thing and point out that what really powered our growth this quarter was a big increase in AML — that's been the primary force behind it.

Peter Lawson

analyst
#30

Yes. Understood. Thank you. Thanks. So regarding the Chinese sites reopening, how much time is needed before they're running again, when do you expect them to be fully operational, and would that serve as a decent model for Europe and the U.S.?

Chris Bowden

executive
#31

When do we expect all the Chinese sites to be back up. Well, it appears that's occurring right now, and I believe a crucial element for us is examining screening rates, since you need to screen 100 patients to identify 10 who could qualify. AML patients, keep in mind, must also be IC < > ineligible; so that's likely our strongest indicator to begin gaining some understanding of how this is ramping back up and what it means for the overall accrual timeline. I can't stress that enough, because you simply have to consider that figure. Roughly, 30% of patients are IC ineligible, then 10% of that 30% carries an IDH1 mutation, and then a certain portion of those patients qualify for the trial. So that's why we focus so heavily on the funnel, the quantity of patients being screened. And that depends on how many patients are reaching the site. And one of the — I think major effects on AML trials is that AML patients tend to have relatively higher treatment urgency within the oncology spectrum, where nearly everyone is fairly urgent. But picture a really busy hospital that is just overwhelmed and swamped with patients with COVID and handling that, enrolling a patient on a clinical trial versus giving them standard of care, perhaps a choice you simply have to make out of pragmatism.

Peter Lawson

analyst
#32

Excellent, thank you very much. That's really appreciated.

Chris Bowden

executive
#33

Indeed.

Chris Shibutani

analyst
#34

Thanks, and good morning. Regarding Mitapivat at EHA in the thalassemia opportunity, could you remind us if we'll see any information in the mid-May abstracts rather than the presentation? And among the 13 patients you'll have there, how many will be evaluable with all the same markers, particularly for hemoglobin? Just a bit more insight into what you'll be able to present. Thanks.

Chris Bowden

executive
#35

Well, some data will be in the abstract, and that will certainly give you a chance to understand a little about that. Certainly, we'll have more information in the presentation. What we plan on doing is presenting data for patients who have safety data, or all patients who've had at least one dose of drug. And then we'll present efficacy data in patients who have made it out to 12 weeks. So when we were at Ash, we spoke to eight patients, and since then we've enrolled a total of 20. And then our data cut will dictate, and the duration of follow-up is, how many patients get in with both alpha and thalassemia. It won't be the complete data set; so then we'll follow up with that, but we would anticipate that we'd have a sizeable portion of those patients that you'll be able to get a good sense of both efficacy and safety.

Chris Shibutani

analyst
#36

Understood. Then, just to verify regarding the sickle cell opportunity, my understanding is that 25 patients were planned for enrollment. Did that number actually get reached, and even though the NIH Group chose against the virtual presentation, were enrollment targets met?

Bruce Car

executive
#37

Regarding the NIH study, Chris, they have the ability to enroll as many as 25 patients. I believe their final sample size will probably land somewhere between 15 and 25. They could assess 15 evaluable patients and halt, or they could continue all the way to 25. Given the amendment allowing up to 100 mg b.i.d., I'm not certain—they haven't shared their precise accrual strategy with us, and I think the real figures depend heavily on how quickly they can reopen.

Chris Shibutani

analyst
#38

Excellent. Finally, concerning the 946, you're introducing a sickle cell cohort—help us understand how many patients that could involve, and perhaps some indication of where you've typically been able to, as we think, potentially learn from those sorts of results?

Chris Bowden

executive
#39

No guidance yet on when we'll be in a position to share results, since that trial hasn't started; the pandemic is impacting it. And we won't be—we're not prepared to reveal the sample sizes, as some of that would hinge on what we observed in the healthy volunteer portion of the study.

Chris Shibutani

analyst
#40

Thanks a lot. I appreciate the updates on all the programs.

Chris Bowden

executive
#41

Indeed.

Alethia Young

analyst
#42

Hi everyone, I appreciate you letting me ask, and I hope all is well on your end. I might have a few things to ask — first, could you share some thoughts, and I realize this has surely been pushed back, on your level of commitment and attention when it comes to possibly holding discussions with Bristol regarding IDHIFA? Then I also wanted to ask whether there might be any chance tied to the fact that venetoclax is, clearly, somewhat harder to give to patients than the treatments and medications you have in IDH? And has that looked like something that could be sent your way? My third item concerns the 2 ACTIVATE studies — my impression, at least, was that the one that's smaller might perhaps read out before the one that's larger. So I was curious whether you can offer any sort of order or detail given the revised guidance you provided today? Thank you.

Jacqualyn Fouse

executive
#43

Hello Alethia, this is Jackie. Regarding your question about Bristol and IDHIFA, that product remains a strong partnership with BMS Celgene under the agreement from 2010. We also keep copromoting IDHIFA alongside them within the U.S., and that partnership is going quite well, just as it has for close to 10 years. As we hear it from Bristol, they currently want to keep their rights to lead on IDHIFA and preserve our relationship in its current form. So we will keep serving IDH patients together with our partner BMS. Anything else?

Chris Bowden

executive
#44

And I can pick up, oh sorry go ahead Jackie.

Jacqualyn Fouse

executive
#45

Hey Chris or Darrin, I don't know who the next question should pick up.

Chris Bowden

executive
#46

Jackie, I'll take that second question. So when it comes to venetoclax, which I brought up earlier, several treatment recommendations came out during the past month. What I'm attempting to do is give the community some direction on managing AML patients while each institution's practice deals with the consequences of COVID-19. Those guidelines lean toward using oral therapies whenever feasible, so that visits to practices, transplants, or infusions — all of it — are kept to a minimum. So on the whole, in this market, orals are preferred because of safety concerns, and ideally orals that deliver meaningful efficacy along with safety. As for venetoclax specifically, I'm not in a position to speak to its overall profile. What matters, I believe, is that physicians are weighing how a drug gets administered, and also how easy it is to handle the safety profile, or the convenience tied to the treatment, given that these patients will be farther away. And I think all of that taken together reflects well on us, both among newly diagnosed patients and in the relapsed refractory setting.

Jacqualyn Fouse

executive
#47

And ACTIVATE-T, correct.

Chris Bowden

executive
#48

Yeah, so Alethia, this is Chris speaking. Regarding those 2 studies, although there could be some sites that overlap, certain locations are conducting them separately. At some locations, only ACTIVATE is underway; at others, only ACTIVATE-T; and at still others, both are happening. So, in terms of sequencing—how COVID might affect our capacity to access sites and retrieve data, and so on—I'm unable to give you any direction on that. No, our initial guidance stated that topline data for both trials would be delivered by the end of the year. And so, as I mentioned during my prepared remarks, COVID has had an effect on that, and when we do release topline data, it will include both trials, so that remains the same. Another point, returning to the question from Chris Shibutani at Cowen. In my prepared remarks, you raised the topic of thalassemia. Actually, as I noted in my prepared remarks, we have 13 efficacy of our patients that we submitted in the abstract; so you will see that.

Michael Schmidt

analyst
#49

Hi everyone, I appreciate you letting me ask. My first one concerns AG-946. I realize this backup, so to speak, Mike, was made to have reduced aromatase inhibition losses in order to pivot, but I'm curious whether there are additional features that could differ, whether potency or selectivity or whatever else might, I suppose, make this molecule's profile even better, and how do you view positioning it over the longer term in hemoglobinopathy as well as in PKD? And my second question really relates to TIBSOVO — we've heard from other companies that there was a bit of warehousing in certain instances of oral cancer drugs during the early part of the COVID-19 crisis. I'm simply curious whether anything similar has shown up in your situation? Thank you.

Chris Bowden

executive
#50

All right, Mike, this is Chris Bowden speaking about 946. Although aromatase inhibition with mitapivat hasn't been an issue to-date, it's something we keep monitoring, and it isn't blocking its development, so we can move that molecule forward. At the same time, AG-946 possessed several additional attributes beyond lacking off target effects on aromatase that could make it a superior molecule. We believe its pharmacokinetic properties might allow for once daily dosing. It's more potent against wild type than mitapivat; and when it comes to pyruvate kinase deficiency, it shows some activity against a few of the — a few mutants that we've observed as being fairly non-responsive to mitapivat. So it could potentially be a better molecule from an efficacy standpoint and a convenience standpoint across all indications, and it could potentially have a broader spectrum of activity and be part of a kinase deficiency. That said, I want to stress that we can and currently we're running many pivotal trials, execution with the ACTIVATE and PK deficiency, planning in thalassemia with mitapivat, so we have considerable confidence in that molecule. I believe Darrin you have the second part, correct?

Darrin Miles

executive
#51

Yeah, so about the warehousing question — we reached out to both our customers and our distributors to confirm we have accurate information on that specific point. And as you may remember, our distribution channel is pretty limited in scope. That gives us better visibility and understanding of the way the drugs are handled from a logistics standpoint. So to answer what you asked: no, we haven't seen proof of any stockpiling at all. And on top of that, we've only been told about 1 or 2 cases in which a competitor of ours looked for a patient order covering more than 1 month's supply. So we're reasonably confident there isn't any inventory stockpiling, whether at the practice or institution level, or among patients.

Michael Schmidt

analyst
#52

Thanks, I appreciate you fielding these — that answered a lot.

Mohit Bansal

analyst
#53

Thanks for taking mine as well, and I hope everybody's keeping safe. If I could, I have a few things to ask. First, are there any patterns emerging where certain physicians are picking TIBSOVO instead of an induction regimen, particularly in light of the pandemic? Darrin, let me jump in quickly on the strategy piece before handing things back to you, since I think this one can be handled fast. My question comes from the perspective of older individuals who might qualify for induction on other grounds. The second, more strategic part is this: shouldn't this DHODH change how priorities are ranked, and should we read it as a sign that the company is now treating rare genetic diseases as the main franchise while putting hematology lower for upcoming programs? Thank you.

Jacqualyn Fouse

executive
#54

Sorry for cutting you off, Darrin. No — what I mean is, we'd already intended to determine what we'd do next with DHODH at some point during this year, and honestly, that call ended up being made sooner than we'd anticipated. On top of that, the way both AML and non-Hodgkin's lymphoma — the condition where the drug was being tested — get treated has shifted a great deal as time has passed. So taking that into account, and looking at where we stood when this initiative first launched—plus, as we've mentioned, because enrollment was taking such a long time—we made the call to take that program out of the portfolio and pursue a partnership for it. My own view is that if this drug ever makes it to market, it will most likely be used as part of a combination therapy; and if that's how it ultimately gets developed, we would prefer to do that alongside a partner.

Mohit Bansal

analyst
#55

Understood.

Jacqualyn Fouse

executive
#56

Yeah, that's — there's nothing more to add there, Darrin, my apologies.

Darrin Miles

executive
#57

Yeah, so in terms of your question, if you take a look at the treatment guidelines I mentioned before, the ones from ASH as well as from the institutions that have been seeing a disproportionate share of COVID cases, both of them say it makes sense to think about less intensive treatment choices for patients who might otherwise have qualified for intensive chemotherapy < >. So TIBSOVO would be among those sensible choices for such patients, either by itself or combined with something else, which is what we're seeing the community do on their own initiative. That being said, I haven't heard of any — gotten any feedback suggesting TIBSOVO has actually been started in those treatments as of yet, but it's still relatively early.

Mohit Bansal

analyst
#58

Understood, quite impressive. Thanks.

Mark Breidenbach

analyst
#59

Hello everyone, good morning, and I appreciate you including me. A quick question, likely directed at Chris, regarding ACTIVATE and ACTIVATE-T. I'm curious, given that we may be facing roughly a 6-month wait until topline data compared with earlier guidance, will the follow-up periods for evaluating the endpoints in these studies differ from what the original protocols laid out? And specifically for ACTIVATE-T, I'd like to know — this is the study relying on transfusion dependence and < > hemoglobin response — whether you could speak to how we might separate any decrease in transfusions caused by the drug from patients merely staying away from the clinic because of the pandemic? Any perspective on this would be quite useful?

Darrin Miles

executive
#60

Yes, all right. The initial piece is whether we'd anticipate a delay and follow up. I can't state that with certainty right now, but the way we see it, ACTIVATE-T has 27 patients, so every single one of them matters enormously. Therefore, the one benefit, for lack of a better phrase, is that you know the whereabouts of every individual patient, unlike a 10,000-patient cardiology study where that simply isn't possible. So from what we can determine, we're working very hard to keep up with assessments and ensure patients attend their visits and remain in contact with the investigators; and then regarding your question about whether someone skipped a visit due to COVID, whether because their outpatient clinic, or their clinic, or their physician or group was redirected toward other priorities, we will be able to record that. After that, we'll need to examine how that plays out concerning how many patients were truly impacted when it comes to analyzing those data.

Mark Breidenbach

analyst
#61

All right, that helps. Thanks.

Darrin Miles

executive
#62

One more item I'd mention, and it ties into a few of the broader points we've been making: we, along with other businesses, have now created case report forms so that COVID-related events can be captured, and the documentation piece matters a great deal. Once everything settles down after this, that's going to be a crucial element when it comes to describing what your results look like. And should you review the guidance issued by the agencies, there's a lot of direction there about the way we ought to be approaching this, and we're devoting considerable time to monitoring it. We're likewise speaking with many other companies regarding our approach. In fact, a number of companies — ours included — are engaging with FDA and IRB, so this is a very busy space, and I believe the point you've brought up is genuinely significant.

Mark Breidenbach

analyst
#63

Thanks.

Kennen MacKay

analyst
#64

Hello, and thank you for fielding my question. Congratulations on the Q1 advances and the way you've carried things out in spite of the pandemic. I'd like to ask about mitapivat. Why was the dosing approach for sickle cell disease not the same as for beta thalassemia right from the start? Also, I'm hoping you can shed some light on what drove the clinician's choice to raise the dose in SCD — what was that decision grounded in? And then, a second point on SCD: with all the shifting parts — the new dosing plan, the halt in enrollment, and the withdrawal of the presentation from EHA — you're now going to reach the go, no go call before any of these results have been shown publicly at ASH in December. So I'm just hoping you can help us grasp what has to be observed for things to move ahead in SCD — is it that the motivated < > 80% to 90% of patients must hit a 1 gm/dL hemoglobin response, or if that isn't really the thing you're zeroing in on, then what is, and how confident are you about getting that proof-of-concept? Many thanks.

Chris Bowden

executive
#65

Yes, hi Kennen, this is Chris. Similar to what Tyler asked earlier, we had been discussing our mitapivat data — covering both pyruvate kinase deficiency and thalassemia — in the context of our broader plans while the NIH was assembling their trial. When they were deciding on the duration of patient treatment, given that this was their initial experience with a PKR activator in sickle cell disease patients, they settled — largely, I believe, on the basis of the dried PK dosing range we were investigating — on 5 to 50 mg. Right from the start, since this trial was being brought to patients for the first time, I believe it was quite evident. Anyone who's dealt with the NIH knows it's a hot bed of clinical research, and they bring a great deal of flexibility of thought into their study. So as we've continued moving forward with examining their data and examining our thalassemia data, they made the decision to escalate and add that amendment to 100 mg. They are the sponsor of the trial. At the end of the day, those choices rest with them. At first, their plan covered three dose levels, but more recently they chose to tack on the 100 mg dose once the 50 mg dose had been given. We're fully behind that approach. It's a lot like what happened at ASH, where we called proof-of-concept based on data from eight patients and a topline readout, and now at EHA we'll be presenting a full, far more detailed dataset for the very first time. So things are unfolding in a fairly similar fashion here. The sticking point, I think, is the question weighing on everybody's mind: what's the way to establish proof-of-concept? Which brings us to the central issue: when you look at the full data set, what does it reveal about the two endpoints one could potentially pursue in sickle cell disease — addressing the anemia, meaning the hemolytic anemia and hemolysis, along with the negative effects that follow from it — and likewise what shows up with 2,3-DPG and sickling curves, and in what way does that shape your view on whether occlusive crises might be a viable target? A further essential piece we'll need to look at, despite the fact that the number of patients will be relatively limited, concerns safety. Those are the factors we'll review, we'll go through the data, and we're confident that by the middle of the year we'll be able to determine if we can proceed and take it into the next phases of clinical development.

Kennen MacKay

analyst
#66

Thanks a lot. I really appreciate that.

Andrew Hirsch

executive
#67

And Kennen, Andrew here. To address part of what you just asked — there's another thing worth noting: even if the data isn't visible to you, this is an open label study, and together with NIH we do have access to it. That means our proof-of-concept call can be made using those data.

George Farmer

analyst
#68

Hello, and good morning. I appreciate you taking my questions. About mitapivat, I was just curious whether you have any data on this 100 mg dose — could you remind us how the safety profile appears? Also, Darrin, perhaps you could share your view on how the venetoclax trials, the Phase 3s, combined with low dose < > and hypomethylating agents, might matter. In what ways do you think those findings could affect TIBSOVO penetration in AML?

Chris Bowden

executive
#69

This is Chris speaking. The safety at 100 mg and our experience at that dose come from a few different places. We first tested the drug in healthy volunteers, looking at doses spanning 15 milligrams b.i.d. all the way to 700 mg b.i.d., given across a total of 14 days of dosing. That remains a valuable reference data set for us. Then in Drive PK, as you'll recall, roughly 25 patients were randomized to begin at 300 mg, and later during that trial, for a variety of reasons, we reduced the dose for a number of them. That gives us experience above 100 mg in a patient group. In the thalassemia study, patients go up at six weeks to 100 mg, so we continue to gain experience there. Taking everything together, based on what we've observed thus far, we believe this sits well within an acceptable range from a tolerability standpoint.

Darrin Miles

executive
#70

Today I want to talk about the venetoclax matter. As everyone is aware, the ven LDAC trial did not succeed. In the U.S., among patients given a duly diagnosed label, LDAC usage wasn't especially large. Therefore, our expectation is — we don't anticipate a very significant effect in that area. When it comes to the valley < > trial combining it with HMA, we can likewise figure the consequences will be rather limited. If you recall, our ven has now been on the market for quite a while in this indication. It's well established in treatment, within the patient profiles that doctors judge most appropriate to treat. This extra trial might serve to reaffirm their usage there; yet keep in mind that our frontline approach has centered on those individuals who previously received an HMA for an antigen disorder such as MDS, and our latest market research, conducted after the VIALE-A study was disclosed, keeps demonstrating that we are the regimen physicians favor most for IDH1 positive patients both in the newly diagnosed setting and in the relapsed setting. So after that, we'll be eager to see what the AGILE study shows, since that will represent the more thorough assessment of IVO plus HMA. I'd also note that roughly 50% of TIBSOVO's use in the frontline setting already involves combination with HMA, and the same holds true actually for its use in the first relapse setting, also combined with HMA, even though we don't promote that.

George Farmer

analyst
#71

Excellent, thank you so much.

Andrew Berens

analyst
#72

Thank you. I'd like to ask something further regarding sickle cell, because I understand that all of you intend to reach a go or no-go call prior to any data being available to us. Will there truly be any standardized quality of life measurements, or any effect on vaso-occlusive crisis, factored into that choice? Or would the determination rest purely upon surrogate biomarkers? Also, what role should the next-gen PKR drug play in that choice, given that the distance separating these two assets might be shrinking? Additionally, could you offer a few remarks about this drug's profile and how it could potentially slot into the sickle cell treatment landscape alongside newly approved or currently in-development drugs?

Darrin Miles

executive
#73

Right, so quality of life data isn't something we're gathering; this is an open label, single line study spanning multiple dose ranges, and we are absolutely, without question, gathering safety data. Should patients experience adverse events of any type, vaso-occlusive crisis included, every one of those will be recorded. Whatever way you read that, it must be viewed through the lens of lacking a control; and you could draw certain inferences if you examine the patient's earlier VOC history, assuming that history is sufficiently accurate. So our examination of those data will primarily be from a safety standpoint where VOCs are concerned. Thus, when I refer to the totality of efficacy data, the bulk of what drives our decision centers on hemoglobin laboratory results, secondary markers for chronic hemolysis — are we tackling that, LDH, bilirubin, reticulocyte counts — are those trending favorably? And then there's the pharmacodynamic data set, which would help inform whether you're affecting the shape of the red cell along with its sickling propensity. As for 946, discussing how that molecule would be positioned is genuinely premature, since our efforts have gone toward exploring mitapivat's potential development in sickle cell disease, thalassemia, and other indications. That drug still needs to prove it is safe and accomplishes what we anticipate; so let's reach — let's get past that point, and afterward we can begin considering where it could land within the broader armamentarium regarding PKR activation generally. And finally, supposing we judged mitapivat to be a compelling drug development opportunity in sickle cell, where might a drug of that kind fit? Well, depending on what the NIH data shows us, it's possible this could tackle both sides of the disease — helping with patients' anemia by boosting hemoglobin, and ideally having them feel better. Getting vaso-occlusive crises down would be a win too, plus cutting the general inflammation tied to chronic hemolysis, which we believe might be a very — an outcome from the drug that could link to clinical benefit. At the same time, with global blood and the Novartis molecule that lowered VOCs now on the scene, it's crowded, so we'll have to — or I'd say it's somewhat crowded. So we'll need to think very carefully about which patient populations they enter versus which ones we enter, and that becomes the next order of business if we feel we've got proof-of-concept from this NIH study.

Andrew Berens

analyst
#74

That's great — I appreciate all the detail, thank you.

John Newman

analyst
#75

Hello everyone, good morning, and thanks for fielding my question. This one is brief and it concerns TIBSOVO. I'm curious whether you've noticed any increase in prescriptions coming through the mail, or, since the drug either is or ought to be simpler for patients to use, whether that's showing up on your end?

Darrin Miles

executive
#76

This is Darrin. As you may remember, when it comes to how we distribute overall, roughly one-third of our product goes out through specialty pharmacies specifically. Those, we recognize, will mostly be mail order, and a decent share of what remains moves by mail order too, though it goes through institutions, or else it's dispensed through SPs that are owned by, correct, very large practices. So the way our distribution approach was originally oriented functions nicely in a situation such as this one, where patients might feel more hesitant about visiting the institution pharmacy to pick up their treatment. And we've highlighted four institutions where we have the flexibility to assist those unable to ship the drug through their mail or the pharmacy, so that they can also reach our specialty pharmacy channels to get that done.

John Newman

analyst
#77

All right, that's excellent, thanks.

Jacqualyn Fouse

executive
#78

I appreciate it, operator. Once more, I'd like to express gratitude to each of you for being here with us today. Let me emphasize this point again — even with the difficulties and unknowns facing us while the pandemic keeps unfolding, my enthusiasm stays enormous regarding what we've accomplished throughout each of our 3 focus areas during this year up to now, and I feel tremendous pride in the people at Agios. In wrapping up, I simply wish to offer my thanks to every courageous medical professional and vital employee working the front lines of the COVID-19 pandemic. Each of us ought to hold them in our thoughts daily and recognize what they do on behalf of everyone. As I always do, I'd also like to express appreciation to Agios's extraordinary staff members for their commitment and enthusiasm and for creating change for the patients we serve. Finally, my thanks go out to every patient, caregiver and physician taking part in our clinical trials. Absent them, the work we perform would be impossible, and they too are finding their way through this tough period with tremendous bravery and resolve. Thanks once more, and we can't wait to talk with you before long. Everyone, stay well.

Operator

operator
#79

That brings us to the end of today's program, everyone, and we appreciate your participation. You're free to disconnect at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Agios Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Agios Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Agios Pharmaceuticals, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.